Unlocked is inventing the future of non-pharmaceutical approaches to combat conditions like hyperuricemia, gout, and kidney stones with its genetically engineered probiotics.
About the company
Unlocked is transforming the treatment of metabolic disorders through the power of genetic engineering. By developing targeted probiotic treatments, Unlocked addresses the root causes of conditions such as hyperuricemia, gout, and kidney stones, providing a novel approach that improves patient outcomes without the side effects associated with conventional drugs.
The prevalence and impact of these metabolic disorders highlight the urgent need for Unlocked's innovative treatments. Traditional pharmaceutical interventions come with limitations and adverse effects, underscoring the significance of Unlocked's safer, more effective alternatives. With its lead products, UA158 and OXO16, Unlocked targets the metabolic pathways associated with uric acid and oxalate accumulation, showcasing a promising leap forward in healthcare.
Unlocked's commitment to scientific rigor, patient-first healthcare, and a preventative approach to medicine positions it as a key innovator in the field. The company not only aims to treat diseases but also enhances the quality of life, leading the charge towards a future where individuals can achieve optimal health and well-being.
Why We Invested
Treatments for metabolic disorders often come with significant limitations and adverse side effects. Unlocked addresses these challenges through its innovative use of genetic engineering to develop targeted probiotic treatments. By focusing on the root causes of conditions such as hyperuricemia, gout, and kidney stones, Unlocked offers a novel approach that enhances patient outcomes without the drawbacks of conventional pharmaceuticals.
The prevalence and impact of these metabolic disorders underscore the urgent need for Unlocked’s safer and more effective alternatives. Their lead products, UA158 and OXO16, target critical metabolic pathways associated with uric acid and oxalate accumulation, representing a significant advancement in healthcare. This targeted approach not only improves the effectiveness of treatments but also minimizes side effects, setting a new standard in patient care.
Unlocked’s dedication to scientific excellence and a patient-first approach aligns with our commitment to investing in innovative health solutions. Their preventative methodology and focus on enhancing the quality of life make them a standout innovator in the field. By supporting Unlocked, we are investing in a future where advanced biotechnological solutions transform the management of metabolic disorders, leading to better health and well-being for individuals worldwide.